Policy Developments - The National Healthcare Security Administration announced that by November 1, 25 provinces, covering nearly 90% of the coordinated areas, will implement direct payment of maternity allowances to individuals [2] Drug and Medical Device Approvals - Jincheng Pharmaceutical's subsidiary received a drug registration certificate for a new antibacterial injection, which is effective against infections caused by sensitive bacteria [5] - Jiukang Bio announced the receipt of a medical device registration certificate for a test kit used to measure NT-proBNP levels in blood, enhancing the company's product offerings [6] - Xuantai Pharmaceutical received temporary approval from the FDA for its extended-release formulation of sitagliptin and metformin, which is used for managing type 2 diabetes [7] Financial Reports - Xiangsheng Medical reported a 41.95% year-on-year increase in net profit for Q3 2025, despite a 6.68% decline in revenue [9] - Weili Medical achieved a 16.09% increase in revenue for Q3 2025, with a net profit growth of 16.31% [10] Capital Market Activities - Riltide Medicines completed a seed round financing of several million RMB, aimed at advancing clinical research and developing an AI molecular design platform [12] - Yaojie Ankang announced plans to convert 44.97 million domestic shares into H-shares, representing approximately 11.33% of the total shares, pending regulatory approval [13] Industry Events - The National Medical Products Administration held a meeting to discuss the regulation of home medical devices, emphasizing the importance of quality management and regulatory compliance [15] - A custom brain-machine interface MRI platform was launched, marking a significant advancement in the clinical application of brain-machine interface technology [16] Shareholder Actions - Kangchen Pharmaceutical's major shareholder reduced their stake by 1.2%, decreasing their ownership from 46.65% to 45.45% [18]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received a drug registration certificate for Morpholine Nitrozole Sodium Injection from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of October 20 [2] - The drug registration certificate is a significant regulatory milestone for the company [2] - This development may enhance the product portfolio and market presence of Jincheng Pharmaceutical [2]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received a drug registration certificate for a new injection, indicating a significant development in its product portfolio and potential market expansion [1] Company Summary - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, has been granted a registration certificate by the National Medical Products Administration for the injection of Morpholine Nitrosyl Sodium [1] - The newly approved drug is indicated for treating infections in adults (≥18 years) caused by sensitive bacteria, which may enhance the company's therapeutic offerings [1] Industry Summary - The approved drug targets several types of infections, including pelvic inflammatory disease caused by Streptococcus and Bacteroides, as well as appendicitis and mixed infections involving anaerobic and aerobic bacteria [1] - This development reflects ongoing advancements in the pharmaceutical industry, particularly in addressing complex bacterial infections [1]

智通财经APP讯，金城医药(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司(简称"金城金 素")的通知，金城金素收到国家药品监督管理局下发的吗啉硝唑氯化钠注射液药品注册证书。 公告显示，吗啉硝唑为5-硝基咪唑类抗菌药物，本品通过将奥硝唑中不稳定的氯离子改为较为稳定的吗 啉环，使其结构更稳定，且不良反应发生率更低。本品适用于敏感细菌引起的下列成人(≥18岁)感染：1. 由包括消化链球菌、脆弱拟杆菌、韦荣球菌、吉氏拟杆菌等引起的妇科盆腔炎(包括子宫内膜炎、输卵 管炎、输卵管卵巢脓肿、盆腔腹膜炎等);2.由包括拟杆菌属(脆弱拟杆菌、卵形/多型拟杆菌、单形拟杆 菌、普通拟杆菌、拟杆菌属)，梭菌属(产气荚膜梭菌、双酶梭菌、丁酸梭菌及其他梭菌)，梭杆菌属(具 核梭杆菌、可变梭杆菌)，厌氧球菌(消化链球菌、韦荣球菌)等引起化脓性阑尾炎、坏疽性阑尾炎;3.由 于厌氧菌和需氧菌引起的混合性感染盆腔炎、阑尾炎等。 ...

公告显示，吗啉硝唑为5-硝基咪唑类抗菌药物，本品通过将奥硝唑中不稳定的氯离子改为较为稳定的吗 啉环，使其结构更稳定，且不良反应发生率更低。本品适用于敏感细菌引起的下列成人(≥18岁)感染：1. 由包括消化链球菌、脆弱拟杆菌、韦荣球菌、吉氏拟杆菌等引起的妇科盆腔炎(包括子宫内膜炎、输卵 管炎、输卵管卵巢脓肿、盆腔腹膜炎等);2.由包括拟杆菌属(脆弱拟杆菌、卵形/多型拟杆菌、单形拟杆 菌、普通拟杆菌、拟杆菌属)，梭菌属(产气荚膜梭菌、双酶梭菌、丁酸梭菌及其他梭菌)，梭杆菌属(具 核梭杆菌、可变梭杆菌)，厌氧球菌(消化链球菌、韦荣球菌)等引起化脓性阑尾炎、坏疽性阑尾炎;3.由 于厌氧菌和需氧菌引起的混合性感染盆腔炎、阑尾炎等。 金城医药（300233）(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司(简称"金城金素")的 通知，金城金素收到国家药品监督管理局下发的吗啉硝唑氯化钠注射液药品注册证书。 ...

Core Viewpoint - Jincheng Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its product, Morinazole Sodium Chloride Injection, which is a new antibacterial drug with lower adverse reaction rates and broader applications in treating various infections [1] Group 1: Product Details - Morinazole is a 5-nitroimidazole class antibacterial drug that improves stability by replacing the unstable chloride ion in ornidazole with a more stable morpholine ring [1] - The drug is indicated for adult infections caused by sensitive bacteria, including gynecological pelvic inflammatory diseases and mixed infections of appendicitis [1] Group 2: Indications - The product is suitable for treating pelvic inflammatory diseases caused by bacteria such as Streptococcus, Bacteroides, and Clostridium [1] - It also addresses purulent appendicitis and necrotizing appendicitis caused by anaerobic and aerobic bacteria [1]

Group 1 - The core point of the article is that Shijiazhuang Pharmaceutical Group (02005.HK) has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Ambroxol Hydrochloride, to be used in marketed formulations. Ambroxol Hydrochloride is an expectorant primarily used for treating respiratory diseases [1] - The company also announced that it has obtained production registration approvals for Calcium Gluconate and Sodium Chloride Injection (100ml:1g/0.8g) and Metronidazole Sodium Chloride Injection (100ml:0.5g/0.9g) [1]